# TLR9/MyD88/NF-κB signaling mediates mental stress-induced exacerbation of psoriasis through immune dysregulation in a mouse model

**Authors:** Qiuhe Song, Dongyang Li, Zhihao Yuan, Chaowen Zhang, Jianqiao Wang, Fangfang Liao, Pengfei Xu, Qipeng Xiao, Sadiq Umar, Sadiq Umar, Sadiq Umar

PMC · DOI: 10.1371/journal.pone.0344474 · 2026-03-06

## TL;DR

This study shows that mental stress worsens psoriasis by activating immune pathways in a mouse model, offering new insights into the disease's progression.

## Contribution

The study identifies the TLR9/MyD88/NF-κB signaling pathway as a novel mediator of mental stress-induced psoriasis exacerbation.

## Key findings

- Mental stress activates the TLR9/MyD88/NF-κB pathway and increases inflammatory factors in psoriasis.
- Stress alters the Th17/Treg and Treg/CD4+T cell ratios, contributing to immune dysregulation.
- Therapeutic interventions targeting the pathway reduce inflammation and psoriasis severity.

## Abstract

Psoriasis is a chronic inflammatory autoimmune disease that affects physical and mental health. Mental stress has been shown to exacerbate human psoriasis by unknown mechanism.

Peripheral blood mononuclear cells (PBMCs) were collected from patients with psoriasis and mental stress-treated psoriatic mice. The expression levels of TLR9/MyD88/NF-κB pathway-related molecules were analyzed by qRT-PCR and western blotting. Histological examination of skin lesions was examined using hematoxylin-eosin staining. The ratios of Treg/CD4+T cells and Th17/Treg cells were determined by flow cytometry. The associations among mental stress, the TLR9/MyD88/NF-κB pathway, and psoriasis were explored using pharmacological inhibitors and lentiviral transfection.

Our findings demonstrated a significant upregulation of TLR9/MyD88/NF-κB pathway-associated molecules in the PBMCs of psoriasis patients, accompanied by elevated expression of inflammatory factors. These observations were validated using a mouse model of psoriasis. Notably, mental stress was shown to activate the TLR9/MyD88/NF-κB pathway and enhance inflammatory factor production, while simultaneously increasing the Th17/Treg ratio and decreasing the Treg/CD4+T ratio. Therapeutic interventions including antipsychotic sertraline, pathway-specific inhibitors, and lentiviral transfection significantly ameliorated inflammatory markers and improved psoriasis severity grading.

The results of this study demonstrates that mental stress induces inflammation and immune dysregulation, exacerbating psoriasis progression. These findings provide valuable insights into the pathophysiological mechanisms underlying psoriasis progression, particularly the mental stress-mediated immunoregulatory axis.

## Linked entities

- **Genes:** TLR9 (toll like receptor 9) [NCBI Gene 54106], MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Chemicals:** sertraline (PubChem CID 68617)
- **Diseases:** psoriasis (MONDO:0005083)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Myd88 (myeloid differentiation primary response gene 88) [NCBI Gene 17874], TICAM1 (TIR domain containing adaptor molecule 1) [NCBI Gene 148022] {aka IIAE6, MyD88-3, PRVTIRB, TICAM-1, TRIF}, TLR9 (toll like receptor 9) [NCBI Gene 54106] {aka CD289}, Il2ra (interleukin 2 receptor, alpha chain) [NCBI Gene 16184] {aka CD25, Il2r, Ly-43}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Tlr9 (toll-like receptor 9) [NCBI Gene 81897], Apc (APC, WNT signaling pathway regulator) [NCBI Gene 11789] {aka CC1, Min, mAPC}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, Foxp3 (forkhead box P3) [NCBI Gene 20371] {aka JM2, scurfin, sf}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 423021] {aka CIAS1, NLRPL, Nalp3}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Il23a (interleukin 23, alpha subunit p19) [NCBI Gene 83430] {aka IL-23, p19}, IL23A (interleukin 23 subunit alpha) [NCBI Gene 51561] {aka IL-23, IL-23A, IL23P19, P19, SGRF}
- **Diseases:** Psoriasis (MESH:D011565), neuroimmune dysregulation (MESH:D021081), major depressive disorder (MESH:D003865), psoriatic (MESH:D015535), pulmonary inflammation (MESH:D011014), autoimmune disease (MESH:D001327), obesity (MESH:D009765), anxiety (MESH:D001007), diabetes (MESH:D003920), pulmonary pathological damage (MESH:D008171), psychiatric (MESH:D001523), drug abuses (MESH:D019966), neurotoxicity (MESH:D020258), psoriatic skin lesions (MESH:D012871), dyslipidemia (MESH:D050171), Inflammatory (MESH:D007249), muscle damage (MESH:D009133), overdose (MESH:D062787), immune dysregulation (OMIM:614878), depression (MESH:D003866), immune disorder (MESH:D007154), colitis (MESH:D003092), infections (MESH:D007239), hypertension (MESH:D006973), lung epithelial cell injury (MESH:D009375)
- **Chemicals:** ethanol (MESH:D000431), DEHP (MESH:D004051), SDS (MESH:D012967), TRIzol (MESH:C411644), isoflurane (MESH:D007530), ST2825 (MESH:C525002), lycopene (MESH:D000077276), water (MESH:D014867), pentobarbital sodium (MESH:D010424), xylene (MESH:D014992), PDTC (MESH:C066229), PS (MESH:D010758), evodiamine (MESH:C049639), formaldehyde (MESH:D005557), DAPI (MESH:C007293), PVDF (MESH:C024865), ODN2088 (MESH:C000626952), imiquimod (MESH:D000077271), eosin (MESH:D004801), PBS (MESH:D007854), Sucrose (MESH:D013395), vaseline (MESH:D010577), SYBR Green (MESH:C098022), polystyrene (MESH:D011137), Sertraline (MESH:D020280), oxymatrine (MESH:C037573), hematoxylin (MESH:D006416), sulfamethoxazole (MESH:D013420), H&amp;E (MESH:D006371), Alexa Fluor 700 (-)
- **Species:** Ctenopharyngodon idella (grass carp, species) [taxon 7959], Mus musculus (house mouse, species) [taxon 10090], Gallus gallus (bantam, species) [taxon 9031], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** Line151 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_UI49)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12965552/full.md

---
Source: https://tomesphere.com/paper/PMC12965552